FREQUENCY THERAPEUTICS, INC. (FREQ): Price and Financial Metrics


0.16 (+14.41%)

POWR Rating

Component Grades













Add FREQ to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where FREQ ranks best; there it ranks ahead of 62.01% of US stocks.
  • The strongest trend for FREQ is in Growth, which has been heading up over the past 179 days.
  • FREQ ranks lowest in Momentum; there it ranks in the 12th percentile.

FREQ Stock Summary

  • FREQ's went public 2.49 years ago, making it older than merely 6.87% of listed US stocks we're tracking.
  • In terms of twelve month growth in earnings before interest and taxes, Frequency Therapeutics Inc is reporting a growth rate of 206.9%; that's higher than 89.91% of US stocks.
  • Revenue growth over the past 12 months for Frequency Therapeutics Inc comes in at -61.96%, a number that bests only 2.41% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to FREQ, based on their financial statements, market capitalization, and price volatility, are SAGE, ACRS, AKTS, BLUE, and RETA.
  • FREQ's SEC filings can be seen here. And to visit Frequency Therapeutics Inc's official web site, go to

FREQ Valuation Summary

  • FREQ's price/earnings ratio is -5; this is 113.7% lower than that of the median Healthcare stock.
  • FREQ's EV/EBIT ratio has moved up 16.9 over the prior 23 months.
  • FREQ's price/sales ratio has moved NA NA over the prior 23 months.

Below are key valuation metrics over time for FREQ.

Stock Date P/S P/B P/E EV/EBIT
FREQ 2021-08-31 7.5 1.6 -5.0 -3.3
FREQ 2021-08-30 7.6 1.6 -5.0 -3.3
FREQ 2021-08-27 7.7 1.6 -5.1 -3.4
FREQ 2021-08-26 7.6 1.6 -5.0 -3.3
FREQ 2021-08-25 7.6 1.6 -5.0 -3.3
FREQ 2021-08-24 7.5 1.6 -5.0 -3.3

FREQ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FREQ has a Quality Grade of D, ranking ahead of 8.89% of graded US stocks.
  • FREQ's asset turnover comes in at 0.147 -- ranking 225th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FREQ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.147 1 -0.828
2021-03-31 0.145 1 -1.583
2020-12-31 0.161 1 4.957
2020-09-30 0.145 1 0.830
2020-06-30 0.220 1 0.575
2019-12-31 0.216 1 1.319

FREQ Price Target

For more insight on analysts targets of FREQ, see our FREQ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.50 Average Broker Recommendation 1.7 (Moderate Buy)

FREQ Stock Price Chart Interactive Chart >

Price chart for FREQ

FREQ Price/Volume Stats

Current price $1.27 52-week high $10.90
Prev. close $1.11 52-week low $1.07
Day low $1.08 Volume 705,500
Day high $1.28 Avg. volume 551,089
50-day MA $1.67 Dividend yield N/A
200-day MA $4.82 Market Cap 44.42M


Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. T

FREQ Latest News Stream

Event/Time News Detail
Loading, please wait...

FREQ Latest Social Stream

Loading social stream, please wait...

View Full FREQ Social Stream

Latest FREQ News From Around the Web

Below are the latest news stories about Frequency Therapeutics Inc that investors may wish to consider to help them evaluate FREQ as an investment opportunity.

One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year

Looking at Frequency Therapeutics, Inc.'s ( NASDAQ:FREQ ) insider transactions over the last year, we can see that...

Yahoo | January 14, 2022

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass., January 04, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 40th Annual J.P. Morgan Healthcare Conference.

Yahoo | January 4, 2022

Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc

Investment company Destra Investment Trust (Current Portfolio) buys ThredUp Inc, Etsy Inc, Riskified, Luxfer Holdings PLC, Spero Therapeutics Inc, sells , , 2U Inc, Euronet Worldwide Inc, Sapiens International Corp NV during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Destra Investment Trust.

Yahoo | December 28, 2021

Frequency Therapeutics: FX-322 Associated With Hearing Signal In Placebo-controlled Trial

(RTTNews) - Frequency Therapeutics, Inc. (FREQ) reported the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss. In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test.

Business Insider Markets | December 9, 2021

Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise

Frequency Therapeutics Inc (NASDAQ: FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL). The Phase 1b study, FX-322, was associated with a hearing signal, as shown by improvements by four subjects in a sentence-in-noise test. In the FX-322-113 study, BKB-SIN test improvements were observed in four subjects, all of whom exceeded the 95% critical difference of 3.1 dB SNR, with two subjects showing a 6 dB response. A single placebo patient had a

Yahoo | December 9, 2021

Read More 'FREQ' Stories Here

FREQ Price Returns

1-mo -14.77%
3-mo -59.87%
6-mo N/A
1-year -84.34%
3-year N/A
5-year N/A
YTD -75.24%
2021 -85.45%
2020 101.14%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8067 seconds.